The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.
Study Type
OBSERVATIONAL
Enrollment
80
Seoul National University Hospital
Seoul, South Korea
RECRUITINGCell Mediated Immunity (CMI)
Frequency of positive cellular vaccine response to HZ/su at 1 month post-dose 2
Time frame: from the time of vaccination to 1month post-dose 2
Long-term CMI response
Frequency of positive cellular responses 1 month post-dose 2 and 1, 2, 3, 4, and 5 year(s) post-dose 2.
Time frame: from 1month post-dose 2 to 5year post-dose 2
gE-specific CD4 T-cell
Frequencies of gE-specific CD4 T-cell (expressing ≥2 of 4 assessed activation markers) at baseline, 1 month post-dose 2, and 1, 2, 3, 4, and 5 year(s) post-dose 2.
Time frame: from the time of vaccination to 5 year post-dose 2
Humoral response
Humoral response (anti-gE-Ig level) at baseline, 1 month post-dose 2, and 1, 2, 3, 4, and 5 year(s) post-dose 2.
Time frame: from the time of vaccination to 5 year post-dose 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.